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Introduction
Despite recent medical advances, metastasis, tumor 
relapse and resistance to therapy remain the principal 
causes of death for breast cancer patients. Th  e lack of 
eﬀ  ective therapies calls for an improved understanding of 
the molecular mechanisms driving breast cancer pro-
gres  sion. It is increasingly acknowledged that aberrant 
activation of a latent embryonic program – known as the 
epithelial–mesenchymal transition (EMT) – can endow 
cancer cells with the migratory and invasive capabilities 
associated with metastatic competence [1-3]. Moreover, 
several lines of evidence have converged in recent years 
to support the notion that not all cancer cells within a 
given tumor are equal in terms of their tumor-initiating 
potential. Th  e emerging paradigm posits that tumor 
progression is driven by a small subpopulation of cancer 
cells – termed cancer stem cells (CSCs) or tumor-
initiating cells – that exhibit two deﬁ  ning characteristics: 
the ability to self-renew and the ability to regenerate the 
phenotypic heterogeneity of the parental tumor [4]. CSCs 
have thus been implicated both in initiating and sus  tain-
ing primary tumor growth and in driving the seeding and 
establishment of metastases at distal sites [5-9].
Whereas the CSC hypothesis does not stipulate the cell 
of origin for a particular cancer, it is reasonable to hypo-
thesize that tumors may originate from the transfor-
mation of normal adult tissue stem cells or from more 
diﬀ  erentiated progenitors that have acquired self-renewal 
capabilities [4] (Figure 1). Importantly, recent studies 
have established a crucial link between passage through 
EMT and the acquisition of molecular and functional 
properties of stem cells [10,11]. Th  us, in addition to 
bestowing migratory and invasive potential, induction of 
EMT in im  mortalized and transformed human 
mammary epithe  lial cells signiﬁ   cantly enhanced their 
self-renewal and tumor-initiating capabilities and led to 
the expression of stem-cell markers, typically associated 
with breast CSCs [10]. As EMT can be sporadically 
triggered by extracellular stimuli and microenvironment 
factors, these ﬁ  ndings provide a plausible explanation for 
the de novo generation of CSCs from diﬀ  erentiated tumor 
cells and suggest that passage through EMT is an 
alternative and/or additional driving force in 
tumorigenesis (Figure 1).
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© 2011 BioMed Central LtdIntriguingly, the gene expression signatures of stem 
cells from normal mouse and human mammary tissues 
and of claudin-low and metaplastic breast tumors share 
strong similarities with the gene expression proﬁ  les of 
cells that have undergone EMT [10,12-16]. Th   is has im-
pli  cations for the origin of these breast tumor subtypes, 
as it remains unclear whether they derive from cells that 
have undergone EMT or whether they represent an 
expan  sion of a pre-existing stem cell population that 
already expresses EMT-associated markers [15,17] 
(Figure 1).
In the present review, we bring together the current 
evidence linking EMT and stem cell attributes and 
discuss the ramiﬁ  cations of these newly recognized links 
for our understanding of the emergence of distinct breast 
cancer subtypes as well as breast cancer progression, 
Figure 1. Epithelial–mesenchymal transition and stem cell traits in breast cancer progression. Breast tumors may originate from the 
transformation of normal adult tissue stem cells or from more diff  erentiated progenitors that have acquired self-renewal capabilities (left panel). 
Moreover, a subset of resident mammary gland stem cells (MaSCs, in blue) exhibit epithelial–mesenchymal transition (EMT) features a priori. The 
EMT features of metaplastic and claudin-low breast tumors may thus signify either that they derive from cells that have undergone EMT or that 
they originate from deregulated expansion of a pre-existing stem cell pool that expresses EMT-associated markers. Additionally, the induction of 
sporadic EMT within a tumor bestows migratory and invasive potential coupled with self-renewal capabilities to cancer cells, generating cancer 
stem cells (CSCs) (right panel). Following extravasation and upon encountering an altered local microenvironment, CSCs (in red) may at least 
partially revert to an epithelial phenotype (mesenchymal–epithelial transition (MET)) to allow adhesion and proliferation at distal sites. As sporadic 
EMT and MET are triggered by extracellular stimuli and microenvironment factors, this model provides a plausible explanation for the de novo 
generation of CSCs from diff  erentiated tumor cells and suggests that passage through EMT and MET is an alternative and/or additional driving force 
in breast tumorigenesis.
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CSC phenotypes have been independently linked with 
metastatic progression, drug resistance and disease 
recurrence [14,18-20].
Epithelial–mesenchymal transition
EMT is an essential developmental process that enables 
reprogramming of polarized epithelial cells towards a 
mesenchymal motile phenotype. During normal 
embryonic development, EMT serves to loosen cell–cell 
contacts and to enhance intrinsic cell motility, thus 
paving the way for the extensive cell movements required 
for gastrulation and organogenesis [1,3]. In normal adult 
tissues, the typically dormant EMT program is reacti  va-
ted during wound repair and tissue regeneration. Dys-
regulation of EMT, however, can lead to pathologic 
conditions such as organ ﬁ  brosis and tissue destruction. 
Indeed, as mentioned above, nonmetastatic cancer cells 
may harness the EMT program to attain the migratory 
and invasive potential required for metastatic progression 
[1,3]. Th  is profound phenotypic conversion from an 
epithelial phenotype to a spindle-shaped morphology is 
orchestrated by integrated networks of signal transduc-
tion pathways and EMT-related transcription factors 
(TFs) that direct the altered expression of genes involved 
in cell adhesion, diﬀ  erentiation and motility. A critical 
molecular event underpinning the dissolution of cell–cell 
contacts during EMT is the loss of E-cadherin, a key 
component of adherens junctions. While the initial stages 
of EMT may involve endocytosis and lysosomal degrada-
tion of E-cadherin [21], EMT and metastatic progression 
are most often associated with a reversible down  regu-
lation of E-cadherin (encoded by CDH1) involving either 
hypermethylation of the CDH1 promoter or repression 
by EMT-inducing TFs [1,3].
Th  e loss of E-cadherin releases β-catenin into the 
cytosol and elicits activation of the canonical Wnt signal-
ing pathway [1,3]. Moreover, the impairment of E-cadherin 
function, together with the downregulation of compo-
nents of tight junctions and desmosomes (for example, 
claudins, occludins, desmogleins and desmocollins) and 
polarity genes, contributes to the dissolution of inter-
cellular contacts and the loss of apico-basal polarity [1,3]. 
However, EMT is not merely a shedding of epithelial 
characteristics but also entails the de novo expression of 
mesenchymal-associated genes (for example, N-cadherin, 
ﬁ   bronectin, α-smooth muscle actin, vimentin). Th  e 
ensuing reorganization of the actin cytoskeleton and the 
intermediate ﬁ   lament network and the acquisition of 
front–back polarity dramatically alter the cellular archi-
tecture, while the secretion of extracellular matrix 
compo  nents and matrix metalloproteinases remodels the 
extracellular matrix. Collectively, these changes disrupt 
the contiguity of the tissue epithelium and render the 
cells intrinsically able to migrate – independent of one 
another – and to invade the underlying stromal compart-
ment by breaching the basement membrane [1,3].
Whereas the migratory and invasive capabilities 
imparted by EMT facilitate the initial steps of the meta-
static cascade, it is envisaged that, following extravasation 
and upon encountering an altered local microenviron-
ment, disseminated cancer cells may at least partially 
revert to an epithelial phenotype to allow adhesion and 
proliferation at distal sites. Th   is reversal of EMT – known 
as mesenchymal–epithelial transition (MET) – has been 
evoked to explain the ﬁ  ndings that disseminated tumor 
cells in the bone marrow often exhibit an epithelial 
phenotype [22] and that distant metastases resemble 
glandular structures with the same molecular subtype as 
their respective primary tumors [23]. Accordingly, the 
induction of MET was recently shown to increase the 
number of macroscopic lung nodules formed by 4T1 
cells, suggesting that acquisition of an epithelial-like 
pheno  type through MET promotes colonization [24]. 
Cancer-associated EMT may therefore not represent a 
complete interconversion of epithelial and mesenchymal 
phenotypes nor an irreversible commitment to a full-
blown mesenchymal state. Indeed, the existence of a 
meta  stable or partial EMT phenotype, exhibiting both 
epithelial and mesenchymal features, is a notion more 
easily reconciled with the concept of a highly plastic 
stem-like state, which is reversible and under the inﬂ  u-
ence of the local microenvironment [25]. Consistent with 
this hypothesis, in a mouse model of EMT induced by 
inﬁ  ltrating CD8 T cells, EMT-derived mesenchymal cells 
exhibited combined luminal and basal markers, providing 
in vivo evidence for the occurrence of a partial EMT [26]. 
Moreover, Damonte and colleagues documented the 
wide  spread occurrence of cells exhibiting dual staining 
for epithelial and mesenchymal markers in a subset of 
EMT-type spindle tumors in mouse models [27]. More 
recently, epithelial cells coexpressing cytokeratins 5/19 
and vimentin were identiﬁ   ed by dual immuno  ﬂ  uores-
cence labeling in claudin-low and basal-like breast cancer 
subtypes [2], conﬁ   rming the existence of cells with 
combined epithelial and mesenchymal characteristics in 
human tumors.
EMT can be induced by a plethora of extracellular 
stimuli, including hepatocyte growth factor, epidermal 
growth factor, platelet-derived growth factor, Wnt, 
Notch, Sonic hedgehog and transforming growth factor 
beta (TGFβ) as well as components of the extracellular 
matrix such as collagen and hyaluronic acid and adverse 
conditions such as hypoxia [1,3]. Th  ese diverse stimuli 
trigger a multitude of signal transduction pathways that 
converge on several EMT-inducing TFs, including Snail, 
Slug, Zeb1, Zeb2, Twist, FoxC2 and Goosecoid, many of 
which are frequently overexpressed in breast cancers [1,3].
May et al. Breast Cancer Research 2011, 13:202 
http://breast-cancer-research.com/content/13/1/202
Page 3 of 10Cellular hierarchy in the normal mammary gland
Th  e human breast is a complex secretory organ that 
comprises an elaborate branching network of epithelial 
ducts embedded in a fat pad, rich in adipocytes, blood 
vessels, hematopoietic cells and stromal ﬁ  broblasts. Th  e 
ducts are lined with an inner layer of luminal epithelial 
cells and an outer layer of contractile basal myoepithelial 
cells that promote the extrusion of the secreted milk 
from the alveoli during lactation. Th   e ducts terminate in 
small grape-like clusters – termed the terminal ductal 
lobular units – that comprise the direct precursors of the 
lobuloalveolar units that produce milk during lactation. 
Pregnancy hormones elicit the expansion and diﬀ  eren-
tiation of alveolar luminal cells into secretory cells that 
produce and secrete milk. After weaning, the expanded 
mammary epithelium is returned to the state of the mature 
virgin gland by a process known as involution, which 
involves extensive apoptosis and tissue remodeling [17].
Th  e capacity of the mammary gland epithelium to 
expand and remodel during puberty and repeated cycles 
of pregnancy is highly suggestive of the existence of 
resident mammary gland stem cells (MaSCs) [17]. 
Further support for the existence of MaSCs has come 
from mammary fat pad transplantation assays, whereby 
cell suspensions or mammary gland explants are trans-
planted into a recipient epithelium-divested fat pad. Th  e 
study of the resultant epithelial outgrowths has con-
ﬁ  rmed the existence of pluripotent stem cells [15,28-32] 
capable of regenerating a fully functional mammary tree 
containing luminal and myoepithelial cells that respond 
to pregnancy hormones by generating alveoli, as well as 
duct-limited and lobule-limited multipotent progenitors 
[33]. Moreover, the development of mammosphere assays 
has provided a way to enrich for stem cells/progenitors in 
vitro as well as a surrogate assay of the anchorage-inde-
pendent growth properties and self-renewal capabilities 
of mammary  stem and progenitor cell types [34]. 
Collectively, these studies have begun to shed light on the 
cellular hierarchy inherent in the normal mammary gland 
epithelium. Whereas the precise nature of the inter  medi-
ates remains to be elucidated, it is believed that un-
diﬀ  erentiated estrogen receptor-negative MaSCs give rise 
to a common bipotent progenitor that is the predecessor 
of two distinct lineages: the basal/myoepithelial progeni-
tors and the luminal progenitors. In turn, basal/myoepi-
thelial progenitors generate diﬀ  erentiated myoepithelial 
cells, whereas luminal progenitors diﬀ  erentiate  into 
ductal luminal cells or generate alveolar luminal cells in 
response to pregnancy hormones [17,35].
Mammary gland stem cell phenotypic markers 
associated with EMT
Th   e ability to evaluate the in vivo repopulating activity of 
distinct subsets of mammary gland cells has enabled the 
prospective isolation and characterization of putative 
stem cells and/or progenitors from both mouse [31,32] 
and human [7,28,29] mammary tissues, and has led to the 
identiﬁ  cation of stem cell-associated antigenic markers. 
In the mouse, a single cell with the Lin−/CD24+/CD29high 
antigenic proﬁ   le [31,32] can thus reconstitute a fully 
functional mammary gland. Interestingly, these cells – 
designated as mammary gland repopulating units – 
express cytokeratins 5 and 14, smooth muscle actin, 
vimentin and smooth muscle myosin – markers typically 
associated with basal/myoepithelial cells.
In breast tumors, the CD44+/CD24–/low antigenic 
phenotype deﬁ  nes a subpopulation of breast cancer cells 
enriched for cells with stem-like qualities: namely, the 
ability to self-renew and eﬃ   ciently reconstitute diﬀ  eren-
tiated tumors. In limiting dilution assays, therefore, as 
few as 100 injected CD44+/CD24–/low cells were capable of 
initiating tumors in non-obese diabetic/severe combined 
immunodeﬁ  cient (NOD/SCID ) mice [6], whereas tens of 
thousands of cells with alternate phenotypes failed to 
form tumors. More recently, expression of the enzyme 
aldehyde dehydrogenase 1 (ALDH-1) has been desig-
nated as a marker of normal and malignant breast stem 
cells [7].
Th   e induction of EMT has been associated with the cell 
surface expression of the CD44+/CD24–/low antigenic 
pheno  type [10]. Indeed, a major proportion of circulating 
tumor cells – probably generated by EMT – display com-
bined expression of one or more EMT markers and 
ALDH-1 [36], suggesting that combining the ALDH-1 
and CD44+/CD24–/low expression proﬁ  les may be exploited 
for the isolation/detection of the highly tumorigenic 
subset of EMT-associated breast CSCs. Importantly, 
however, no markers have to date been identiﬁ  ed that 
could distinguish between MaSCs and CSCs. Undoub  t-
edly, future eﬀ  orts will focus on this important area and 
its potential therapeutic implications.
EMT and normal mammary gland development
Interestingly, transient EMT-like events have been 
implicated in the branching morphogenesis that under-
lies mouse mammary gland development. Speciﬁ  cally, 
the restricted expression of Twist-1, Twist-2 and Snail in 
the terminal end buds of the mouse mammary gland 
strongly suggests that these TFs may function to 
transiently repress epithelial diﬀ  erentiation in favor of a 
motile phenotype during the development of the ductal 
networks [37]. Furthermore, in an elegant series of 
organotypic culture experiments, using real-time imaging 
of green ﬂ  uorescent protein expressed under the control 
of the vimentin gene promoter, the position and pattern 
of branch formation was found to mirror the sites of 
transient green ﬂ  uorescent protein expression, suggesting 
dynamic EMT-like events at the branch points [38]. 
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ductal tree exhibit mesenchymal-like features and secrete 
matrix metalloproteinase 3 [39].
Many authors have drawn parallels between the 
branching morphogenesis processes underlying normal 
embryonic mammary gland development and the initia-
tion of invasive events in breast cancer progression, 
based on the fact that, in the developing gland, epithelial 
cells proliferate, migrate and invade from a pre-existing 
epithelium into the adjacent fat pad [40]. Indeed, it is 
envisaged that the signaling pathways orchestrating 
normal mammary gland development and remodeling 
during pregnancy and involution are also the ones that go 
awry during tumor initiation and progression. Consistent 
with this, aberrations in numerous signaling pathways 
and transcription factors implicated in normal mammary 
gland development and EMT have been documented in 
breast cancer progression [1,3].
Breast cancer: a hierarchy in fl  ux
Th   ere is increasing evidence of similar cellular hierarchies 
in the normal and the malignant mammary gland [17,35]. 
Consistent with this, the gene expression proﬁ  le  of 
CD44+/CD24–/low breast cancer cells, enriched for cells 
with tumor-initiating capabilities, more closely resembles 
that of CD44+/CD24–/low cells from the normal breast than 
CD44–/CD24+ cells isolated from the same tumor [41].
Breast cancers have long been recognized as a 
remarkably diverse and heterogeneous set of malig  nan-
cies, owing mostly to their classiﬁ  cation into numerous 
histological subtypes on the basis of several histo  patho-
logical criteria. In recent years, cytogenetic and muta-
tional analyses – in conjunction with molecular proﬁ  ling 
technologies – have revealed that this histologic hetero-
geneity is underpinned by diverse gene expression signa-
tures, thought to represent the diﬀ  erent cell lineages of 
the mammary gland and stages of mammary epithelial 
cell diﬀ   erentiation [4,17]. Using genomic proﬁ  ling,  at 
least six breast cancer intrinsic subtypes have been 
identi ﬁ   ed on the basis of their distinct molecular 
signatures rather than their clinical or histopathologic 
behavior: luminal A, luminal B, HER2+, basal-like, normal 
breast-like and the most recently recognized claudin-low 
[2,12,42,43].
Previously, several studies had alluded to basal-like 
tumors being composed of primitive undiﬀ  erentiated 
cells [44-46]. Honeth and colleagues reported that the 
CD44+/CD24–/low phenotype, associated with populations 
enriched for breast CSCs, was most prominent in basal-
like and, in particular, BRCA1 hereditary breast tumors 
[45]. Moreover, basal-like breast cancers, which are 
enriched for CD44+/CD24–/low  cells, were reported to 
exhibit EMT features that might account for their 
aggressive clinical behavior and metastatic propensities 
[47]. At the molecular level, hypoxia-induced SLUG 
expression had been associated with the acquisition of a 
basal-like breast cancer phenotype characterized by the 
stem cell-regulatory genes CD133 and BMI1 [48]. Recent 
in vivo studies, however, have demonstrated that, despite 
their stem cell-like characteristics, basal-like breast 
tumors may not be derived from normal mammary gland 
stem cells [49] and instead point to the failure of luminal 
progenitors to undergo terminal diﬀ  erentiation as a more 
likely contributor to the emergence of sporadic and 
BRCA1-mutated basal-like breast cancers. Indeed, Lim 
and colleagues found an aberrant expansion of this 
luminal progenitor subpopulation in the pre-neoplastic 
tissues from BRCA1 carriers [29], who are predisposed to 
basal-like breast tumors. Accordingly, interrogation of 
the breast cancer intrinsic subtype gene sets with the 
gene signatures of human MaSC-enriched, luminal 
progenitor, mature luminal and stromal populations 
uncovered hitherto unrecognized similarities between the 
basal-like and luminal progenitor gene signatures [15].
On the other hand, the MaSC (human, CD49fhighEpCAM–; 
mouse, CD29highCD24+CD61+) expression proﬁ  le  most 
closely resembles the claudin-low subtype [2,15]. 
Together, these ﬁ  ndings seem consistent with the notion 
that distinct subsets of breast cancer may derive from the 
diﬀ   erent cell lineages of the mammary gland and/or 
stages of mammary epithelial cell diﬀ  erentiation; that is, 
MaSCs may be the cell of origin for claudin-low tumors, 
and committed luminal progenitors may beget basal-like 
tumors. It is also possible, however, that MaSCs comprise 
the cell of origin for both subtypes but claudin-low 
tumors are locked in a stem-like state portraying MaSC 
features whereas the luminal progenitors are impeded 
from undergoing terminal diﬀ  erentiation [15,29,35].
Th   e newly recognized claudin-low subtype is character-
ized by reduced expression of genes involved in tight 
junctions and intercellular adhesions (for example, 
claudin 3, claudin 4, claudin 7, occludins, E-cadherin), 
diminished expression of luminal diﬀ  erentiation markers 
and enrichment for EMT markers, immune response 
genes and cancer stem cell features (CD44+/CD24–/low; 
CD49f+/EpCAM–/low; high ALDH-1) [2,15]. Although the 
claudin-low and basal-like subtypes share some 
similarities (for example, low HER-2, luminal cyto  kera-
tins, estrogen receptor and GATA-3), it is clear that they 
are distinct subtypes. Indeed, claudin-low tumors lack 
expression of proliferation genes and are hence likely to 
comprise slow-cycling tumors quite unlike the basal-like 
subtype [2]. Yet many of the studies on basal-like tumors 
were conducted prior to the recognition of the claudin-
low subtype as a distinct entity [12]. Previously classiﬁ  ed 
basal-like tumors may thus need to be reassessed with 
tumor classiﬁ  ers that take into account the recently identi-
ﬁ  ed claudin-low subtype. Indeed, recent proﬁ  ling would 
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appreciable mesenchymal or stem-cell like signature [16].
Furthermore, genome-wide transcriptional proﬁ  ling 
has shown that metaplastic breast cancers, a rare and 
aggressive histological subtype, frequently exhibit EMT 
and stem cell-like gene expression [13], probably contri-
buting to their poor outcomes. Indeed, metaplastic and 
claudin-low tumors share many gene expression features, 
although the former are often associated with phospho-
inositide-3-kinase pathway mutations [13].
Most notably, many of the conserved genes in the 
MaSC signature are typically considered EMT-associated 
genes [15]. Th  e expression of these EMT-associated 
genes in tumor cells may therefore reﬂ  ect a basal diﬀ  eren-
tiation program and not necessarily indicate cells that 
have undergone EMT [15]. Th   is is quite distinct from the 
idea that EMT might facilitate the generation of migrat-
ing cancer stem cells due to an altered microenvironment 
at the invasive front [10,50,51].
Similar to breast cancer subtypes, genomic proﬁ  ling 
has also been applied to classify breast cancer cell lines 
into luminal, basal A (mixed basal/luminal features) and 
basal B/mesenchymal types [52-55]. Th  ese cell line 
genomic proﬁ  les broadly mirror the heterogeneity and 
diversity of primary breast tumors, and have helped 
establish a strong correlation between invasiveness, 
meta  static potential, EMT gene expression and CSC 
properties. Th   e basal B/mesenchymal cell lines thus tend 
to be highly invasive, exhibit the CD44+/CD24–/low
 anti-
genic proﬁ   le and display EMT features, including 
reduced E-cadherin levels and selective upregulation of 
ZEB1 [52,53,55]. Indeed, a subset of nine previously 
classiﬁ   ed basal B cell lines (BT549, HBL100, Hs578T, 
MDA-MB-157, MDA-MB-231, MDA-MB-435, MDA-
MB-436, SUM1315, SUM159PT) was more recently 
reported to represent the claudin-low subtype [2], 
strength  en  ing the case for considering basal-like and 
claudin-low tumors and cell lines separately.
Whereas CD44 expression is elevated in both basal A 
and basal B cell lines, CD24 expression levels are 
signiﬁ  cantly lower in the basal B subgroup, suggesting 
that these cell lines are enriched for CSCs [52,53]. Indeed, 
within the basal B cell line subgroup, the levels of CD24 
correlate positively with E-cadherin and negatively with 
vimentin. Moreover, CD44+/CD24–/low cells exhibit activa-
tion of the TGFβ signaling pathway [41], consistent with 
the proposed association between this antigenic proﬁ  le 
and EMT features.
Molecular circuitries linking EMT and stemness
EMT-inducing TFs function either directly or indirectly 
to repress CDH1 transcription, reduce epithelial diﬀ  eren-
tiation and/or promote the mesenchymal gene expression 
program. Recently, several TFs and miRNAs have been 
implicated in the molecular pathways linking EMT to the 
acquisition of stem cell properties, although the precise 
molecular circuitries remain largely undeﬁ  ned.
Recent studies demonstrated that the induction of 
EMT by ectopic expression of SNAIL, TWIST or TGFβ 
treatment in immortalized and transformed human 
mammary epithelial cells results in the acquisition of 
stem cell properties: the ability to self-renew and initiate 
tumors [10,11]. In addition, chronic over expres sion  of  the 
homeobox protein Six1 in the mouse mammary gland 
generated highly aggressive tumors with an EMT 
phenotype, stem cell features and activated Wnt signaling 
[56], providing vital in vivo evidence for the emergence of 
cells with combined EMT/CSC phenotypes.
At the molecular level, TWIST1 directly stimulates the 
expression of BMI1,  which encodes  a polycomb-group 
protein that maintains self-renewal through repression of 
the p16INK4A–ARF locus. Indeed, TWIST1 and BMI1 
cooperate to repress expression of both E-cadherin and 
p16INK4a, thus simultaneously promoting EMT and 
conferring tumor-initiating capabilities [57]. Moreover, 
TWIST1 modulates the CSC phenotype by downregu-
lating the expression of CD24 [58].
Recently, several novel EMT-inducers that appear to 
act either upstream or in concert with the known EMT 
TFs have been implicated in the transcriptional hierarchy 
of EMT and the establishment of the combined EMT/
CSC phenotype. Th   e mammalian Y-box binding protein 1 
(YB1) has been shown to promote cap-independent 
translation of SNAIL, TWIST and ZEB2/SIP1 together 
with the upregulation of the stem cell markers p63, CD44 
and CD10, while at the same time repressing cap-
dependent translation of growth-promoting genes and 
CD24. YB1 thus appears to link the acquisition of a 
mesenchymal/migratory phenotype and stem cell-asso-
ciated gene expression with entrance into a quiescent 
state [59]. Further molecular targets of YB1 in the MDA-
MB-231 and SUM149 breast cancer cell lines have been 
shown to include the stem-cell-associated markers CD44 
and CD49f as well as c-KIT, BMI1 and members of the 
WNT and NOTCH signaling pathways [60].
Another newly identiﬁ  ed player in EMT – the ladybird 
homeobox 1 (LBX1) protein – transcriptionally targets 
ZEB1, ZEB2, SNAIL1 and TGFβ2. Accordingly, ectopic 
LBX1 expression in mammary epithelial cells induced EMT 
and mesenchymal markers with concordant increases in 
mammosphere formation and the proportion of CD44+/
CD24–/low cells [61]. Both YB1 and LBX1 may thus function 
as master regulators of the EMT/stemness program.
Two recent studies have emphasized the role of the 
microenvironment in promoting tumor progression by 
inﬂ   uencing EMT-dependent manifestation of CSC 
properties. First, the activating transcription factor 3 
gene is an adaptive-response gene that may serve to 
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ment with the acquisition of combined EMT/CSC 
properties in mammary epithelial cells [62]. Second, 
signaling by the urokinase-type plasminogen activator 
recep  tor can also instigate EMT and promote CSC 
proper  ties in MDA-MB-468 cells exposed to hypoxia [63].
Th   e discovery of miRNAs has added an additional level 
of complexity to the molecular networks regulating EMT, 
metastasis and stemness [51,64]. Indeed, members of the 
miR-200 family (miR-141, miR-200a, miR-200b, miR-
200c and miR-429) are rapidly emerging as master 
regulators of diﬀ   erentiation by directly targeting the 
transcripts encoding ZEB1 and ZEB2/SIP1, thereby 
leading to de-repression of CDH1 and eliciting MET. In 
turn, ZEB1 can also suppress members of the miR-200 
family, establishing a reciprocal feedback loop [65,66] 
that enables reversible phenotypic modulation of the 
epithelial and mesenchymal states. Consistent with the 
induction of EMT as an important early step in tumor 
metastasis, downregulation of the miR-200 family has 
been extensively documented to occur during EMT and 
in invasive breast cancers [65,66]. Indeed, recently, ZEB1 
has been shown to induce EMT by suppressing miR-200 
family members at the invasive front of pancreatic tumors, 
thus leading to the generation of migrating CSCs [51].
Importantly, downregulation of the miR-200 family has 
also been described in normal murine mammary stem 
cells and human normal and breast cancer stem cells 
(CD44+/CD24–/low), reinforcing the molecular links 
between normal stem cells and CSCs [64] as well as the 
roles of the miR-200 family in regulating stemness and 
EMT. Indeed, the relevant molecular targets of the 
miR-200 family include the stem cell-associated factors 
BMI1, SOX2 and KLF4 [51,64,65].
Other miRNAs have also been implicated in the 
regulation of EMT and CSC traits. Enforced expression 
of let-7, which targets HMGA2 and HRAS, thus sup-
pressed mammosphere formation and tumor initiation in 
serial transplantation assays in NOD/SCID mice, whereas 
suppression of let-7 function in diﬀ  erentiated  cells 
increased mammosphere formation. Accordingly, let-7 
expression levels are reduced in breast CSCs but increase 
during diﬀ  erentiation [67].
EMT, stemness and resistance to chemotherapy
Several lines of evidence suggest that CSCs, including 
those generated through EMT, exhibit intrinsic resistance 
to conventional chemotherapies [14,19,20,68]. Indeed, 
EMT TFs have been directly implicated in subverting key 
tumor suppressor mechanisms. For example, TWIST can 
stimulate AKT2 expression, leading to enhanced cell 
survival and increased resistance to paclitaxel in vitro 
[69], can directly elicit multidrug resistance by inducing 
expression of MDR1 in adriamycin-treated cells [70] and 
can override oncogene-induced senescence in vivo by 
inhibiting key components of the p53-dependent and Rb-
dependent pathways [71].
Many currently administered chemotherapies target 
the rapidly proliferating cells of the tumor bulk but fail to 
eradicate the intrinsically resistant CSCs, thus inadver-
tently leading to expansion of the CSC pool and/or 
selection of resistant CSCs. Accordingly, Creighton and 
colleagues demonstrated that the residual breast cancer 
cell populations, persisting in patients after conventional 
treatments, exhibited gene expression proﬁ  les indicative 
of cells with combined tumor-initiating and mesen  chymal/
claudin-low features [14]. Signiﬁ  cantly, the corresponding 
gene expression signatures may harbor novel molecular 
targets for overcoming the intrinsic therapeutic resis-
tance of breast cancers.
Towards therapeutics that target the EMT/CSC 
phenotype
Taken together, the ﬁ  ndings that link EMT, CSC traits, 
drug resistance and enhanced metastatic competence 
suggest that targeting the EMT/CSC phenotype may 
hold considerable therapeutic promise. In a seminal 
study, Gupta and colleagues performed a high-
throughput chemi  cal screen to identify agents with 
selective toxicity against CSCs generated by EMT. Th  ey 
thus identiﬁ  ed salinomycin, a potassium ionophore that 
reduced the CD44highCD24–/low fraction and impeded 
mammosphere formation. Signiﬁ  cantly, pretreatment of 
EMT-derived CSCs with salinomycin in vitro reduced 
their ability to initiate tumors and lung metastases in 
NOD/SCID mice [72].
Th   e anti-diabetic drug metformin, which has long been 
recognized for its beneﬁ  cial eﬀ  ects in breast cancer, was 
recently shown to selectively kill breast CSCs in vitro and 
in vivo. Moreover, the combination of metformin and the 
DNA-damaging agent doxorubicin reduced tumor mass 
and prevented relapse more eﬀ  ectively than either drug 
alone in a xenograft mouse model [73]. Residual cell 
populations recovered from these tumors after the 
combined treatment were devoid of CSCs demonstrating 
that the therapeutic prowess of metformin – in the 
context of doxorubicin treatment – is linked to its ability 
to kill CSCs. Interestingly, an independent study demon-
strated that metformin treatment reduced the expression 
of the EMT regulators ZEB1, TWIST1, SNAI2 (Slug) and 
TGFβ, decreased the proportion of CD44+CD24–/low cells 
and impeded mammosphere formation in claudin-low 
MDA-MB-231 cells [74].
Recent ﬁ  ndings further conﬁ  rm that monotherapy may 
exacerbate tumor relapse, as doxorubicin treatment 
actually promoted metastasis of murine 4T1 and human 
MDA-MB-231 cells, concurrent with activation of TGFβ 
signaling [75]. Importantly, however, the combination of 
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prevented mammary tumor growth and lung metastases 
in these xenograft models [75]. Together with the 
important clinical ﬁ  ndings of Creighton and colleagues 
[14], these studies highlight the need to combine conven-
tional chemotherapies, radiotherapies or endocrine 
therapies with drugs targeting the self-renewal, survival 
and drug resistance of cells with an EMT/CSC pheno-
type. Moreover, given that CSCs are thought to represent 
only a small fraction of the tumor mass and that the 
eﬀ  ectiveness of current therapies is often measured by a 
reduction in tumor volume, CSC-targeted therapies may 
require new methods of gauging therapeutic success in 
the short term in addition to decreased tumor recurrence 
or increased tumor-free survival.
Concluding remarks
Th   e induction of EMT and its ability to confer stem cell 
properties to cancer cells remains an important factor in 
disease progression irrespective of breast tumor subtype. 
Given that at least a subset of resident MaSCs are 
endowed with EMT features a priori, however, claudin-
low and metaplastic tumors may arise through de  regu-
lated expansion of this MaSC pool. Alternatively, if EMT 
is sporadically triggered by the tumor microenvironment 
(cytokines produced by inﬁ  ltrating immune cells, growth 
factor signaling, hypoxia), it may endow subsets of cancer 
cells with the migratory, invasive and self-renewal 
properties required to further sustain and expand 
primary tumor growth and/or generate migrating CSCs 
that can seed new tumors at distant sites. Nevertheless, 
the molecular circuitries underlying EMT and stemness 
appear closely intertwined, and it will be vital to further 
delineate key molecular players that link these two 
cellular states. Strategies to target the combined EMT/
CSC phenotype, however, may also impact the normal 
MaSC pool or stem cells residing in other tissues. Eﬀ  orts 
to develop CSC-targeted therapeutics must therefore not 
only be focused on the EMT/CSC phenotype but must, 
in parallel, strive to identify novel molecular targets that 
could serve to eradicate CSCs without harming normal 
stem cells. Overall, the close links between EMT, CSC 
traits, drug resistance and enhanced metastatic compe-
tence suggest that an improved understanding of the 
EMT/CSC connection may uncover new therapeutic 
targets for breast cancers, irrespective of their intrinsic 
subtype, since most subtypes harbor a pool of CSCs.
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